Bridging therapy with bispecific antibody before CAR-T for relapsed/refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called a bispecific antibody (which helps your immune system attack myeloma cells) as a 'bridge' treatment before you receive CAR-T cell therapy. The goal is to control the disease better and improve the success of the CAR-T treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has come back or has not responded to at least three different types of treatment.
- You have already had your cells collected (apheresis) to make CAR-T cells.
- You are generally able to care for yourself (ECOG score 3 or less).
- Your blood counts and organ function (liver, kidneys, heart) are within acceptable levels.
- You do not have active infections like hepatitis B, hepatitis C, or HIV.
- You have not had prior treatment with a GPRC5D-targeted therapy (another type of bispecific antibody).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a two-step approach for people with relapsed or hard-to-treat multiple myeloma. First, you get a bispecific antibody (a drug that helps your immune system attack myeloma cells), then you receive CAR-T cell therapy (your own immune cells modified to fight the cancer). The goal is to see if this combination works well together.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to other treatments and has spread to tissues outside the bone marrow.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a new treatment where your own immune cells (T cells) are collected, modified to find and attack myeloma cells, and given back to you. It is for people with multiple myeloma that has come back or not responded to several standard treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
Hear when a new Relapsed Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.